Doxorubicin-induced cardiomyocyte death is mediated by unchecked mitochondrial fission and mitophagy.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 11 7 2019
medline: 26 5 2020
entrez: 11 7 2019
Statut: ppublish

Résumé

Doxorubicin (Dox) is a widely used antineoplastic agent that can cause heart failure. Dox cardiotoxicity is closely associated with mitochondrial damage. Mitochondrial fission and mitophagy are quality control mechanisms that normally help maintain a pool of healthy mitochondria. However, unchecked mitochondrial fission and mitophagy may compromise the viability of cardiomyocytes, predisposing them to cell death. Here, we tested this possibility by using Dox-treated H9c2 cardiac myoblast cells expressing either the mitochondria-targeted fluorescent protein MitoDsRed or the novel dual-fluorescent mitophagy reporter mt-Rosella. Dox induced mitochondrial fragmentation as shown by reduced form factor, aspect ratio, and mean mitochondrial size. This effect was abolished by short interference RNA-mediated knockdown of dynamin-related protein 1 (DRP1), a major regulator of fission. Importantly, DRP1 knockdown decreased cell death as indicated by the reduced number of propidium iodide-positive cells and the cleavage of caspase-3 and poly (ADP-ribose) polymerase. Moreover, DRP1-deficient mice were protected from Dox-induced cardiac damage, strongly supporting a role for DRP1-dependent mitochondrial fragmentation in Dox cardiotoxicity. In addition, Dox accelerated mitophagy flux, which was attenuated by DRP1 knockdown, as assessed by the mitophagy reporter mt-Rosella, suggesting the necessity of mitochondrial fragmentation in Dox-induced mitophagy. Knockdown of parkin, a positive regulator of mitophagy, dramatically diminished Dox-induced cell death, whereas overexpression of parkin had the opposite effect. Together, these results suggested that Dox cardiotoxicity was mediated, at least in part, by the increased mitochondrial fragmentation and accelerated mitochondrial degradation by the lysosome. Strategies that limit mitochondrial fission and mitophagy in the physiologic range may help reduce Dox cardiotoxicity.-Catanzaro, M. P., Weiner, A., Kaminaris, A., Li, C., Cai, F., Zhao, F., Kobayashi, S., Kobayashi, T., Huang, Y., Sesaki, H., Liang, Q. Doxorubicin-induced cardiomyocyte death is mediated by unchecked mitochondrial fission and mitophagy.

Identifiants

pubmed: 31291545
doi: 10.1096/fj.201802663R
pmc: PMC6766652
doi:

Substances chimiques

RNA, Small Interfering 0
Doxorubicin 80168379AG
Ubiquitin-Protein Ligases EC 2.3.2.27
parkin protein EC 2.3.2.27
Caspase 3 EC 3.4.22.-
Dynamins EC 3.6.5.5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11096-11108

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM123266
Pays : United States

Références

Circulation. 2010 May 11;121(18):2012-22
pubmed: 20421521
Exp Mol Pathol. 1987 Feb;46(1):123-35
pubmed: 2879739
PLoS One. 2013 Oct 17;8(10):e77713
pubmed: 24147064
J Mol Cell Cardiol. 2016 Jun;95:57-69
pubmed: 26739215
J Lab Clin Med. 1996 Mar;127(3):272-8
pubmed: 9273360
EMBO J. 2008 Jan 23;27(2):433-46
pubmed: 18200046
Cell Death Dis. 2015 Mar 12;6:e1677
pubmed: 25766316
Circ Res. 2015 Jul 31;117(4):346-51
pubmed: 26038571
Hum Mol Genet. 2013 Apr 15;22(8):1601-14
pubmed: 23314018
Mol Cell Proteomics. 2013 Nov;12(11):3094-107
pubmed: 23882026
Am J Physiol Heart Circ Physiol. 2011 Nov;301(5):H1924-31
pubmed: 21890690
Biomed Pharmacother. 2018 Apr;100:335-348
pubmed: 29453043
Circulation. 2016 Apr 26;133(17):1668-87
pubmed: 26984939
Toxicol In Vitro. 2018 Sep;51:1-10
pubmed: 29729358
J Biol Chem. 2013 Jun 21;288(25):18077-92
pubmed: 23658055
J Clin Oncol. 1997 Apr;15(4):1318-32
pubmed: 9193323
J Cell Biol. 2012 May 14;197(4):535-51
pubmed: 22564413
Compr Physiol. 2017 Sep 12;7(4):1407-1424
pubmed: 28915329
PLoS One. 2015 Jun 29;10(6):e0129303
pubmed: 26121149
Mol Biol Cell. 2013 Mar;24(5):659-67
pubmed: 23283981
Cell Death Dis. 2017 Mar 30;8(3):e2716
pubmed: 28358377
Cell Biol Toxicol. 2009 Jun;25(3):227-43
pubmed: 18386138
Pharmacol Rev. 2004 Jun;56(2):185-229
pubmed: 15169927
Cancer Res. 2001 Jan 15;61(2):771-7
pubmed: 11212281
Cell Metab. 2017 Dec 5;26(6):872-883.e5
pubmed: 29107503
Cell Biol Toxicol. 2007 Jan;23(1):15-25
pubmed: 17009097
Technol Cancer Res Treat. 2008 Dec;7(6):497-516
pubmed: 19044329
J Clin Invest. 2014 Feb;124(2):617-30
pubmed: 24382354
J Biol Chem. 1986 Mar 5;261(7):3060-7
pubmed: 3456345
J Clin Invest. 2014 Sep;124(9):3987-4003
pubmed: 25083992
Cancer. 2003 Jun 1;97(11):2869-79
pubmed: 12767102
Curr Pharm Des. 2011;17(20):2113-29
pubmed: 21718248
Nat Chem Biol. 2012 Oct;8(10):831-8
pubmed: 22922758
Mol Cancer Res. 2009 Jan;7(1):79-87
pubmed: 19147539
J Vis Exp. 2011 Jul 18;(53):null
pubmed: 21788936
Oncotarget. 2017 Jul 11;8(28):46663-46680
pubmed: 28445146
Circ Res. 2016 Sep 30;119(8):909-20
pubmed: 27502479
Nat Commun. 2013;4:2308
pubmed: 23917356
J Clin Oncol. 2007 Feb 10;25(5):493-500
pubmed: 17290056
J Pharmacol Exp Ther. 2012 Apr;341(1):183-95
pubmed: 22209892
J Nippon Med Sch. 2008 Dec;75(6):320-4
pubmed: 19155567
Cardiovasc Toxicol. 2007;7(2):140-4
pubmed: 17652819
Arch Intern Med. 2010 Jul 26;170(14):1247-55
pubmed: 20660845
Cardiovasc Toxicol. 2007;7(2):101-7
pubmed: 17652813
Cardiovasc Toxicol. 2015 Oct;15(4):377-93
pubmed: 25575753
Pharmacol Toxicol. 2003 Sep;93(3):105-15
pubmed: 12969434
J Biol Chem. 1986 Mar 5;261(7):3068-74
pubmed: 3005279

Auteurs

Michael P Catanzaro (MP)

Department of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, USA.

Ashley Weiner (A)

Department of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, USA.

Amanda Kaminaris (A)

Department of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, USA.

Cairong Li (C)

Clinical Medical College, Hubei University of Science and Technology, Xianning, China.

Fei Cai (F)

Hubei Key Laboratory of Diabetes and Angiopathy, Hubei University of Science and Technology, Xianning, China.

Fengyi Zhao (F)

Department of Endocrinology, The First Affiliated Hospital, Xi'an Jiaotong University Health Science Center, Xi'an, China.

Satoru Kobayashi (S)

Department of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, USA.

Tamayo Kobayashi (T)

Department of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, USA.

Yuan Huang (Y)

Department of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, USA.

Hiromi Sesaki (H)

Department of Cell Biology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Qiangrong Liang (Q)

Department of Biomedical Sciences, College of Osteopathic Medicine, New York Institute of Technology, Old Westbury, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH